<DOC>
	<DOCNO>NCT01071304</DOCNO>
	<brief_summary>The purpose study compare pharmacokinetic profile midazolam give alone midazolam give multiple oral dos 40 mg ridaforolimus . Part 1 study design evaluate CYP3A4 activity follow 5 day dose ridaforolimus design efficacy endpoint . Part 2 compassionate-use extension give patient opportunity receive clinically active dose ridaforolimus . Part 2 dose open end limited data collection .</brief_summary>
	<brief_title>Effect Ridaforolimus Pharmacokinetics Midazolam ( Study MK-8669-044 )</brief_title>
	<detailed_description />
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>participant male female participant must histologically cytologicallyconfirmed metastatic locally advanced solid tumor , lymphoma , hematologic malignancy fail respond standard therapy , progress despite standard therapy , standard therapy exist . There limit number prior treatment regimen participant must performance status ≤ 2 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale If participant female must post menopausal ( define free menses ≥1 year follicle stimulate hormone ( FSH ) postmenopausal range screen ) , surgically sterilize ( hysterectomy , oophorectomy tubal ligation ) , childbearing potential , must willing use 2 approve method contraception ( hormonal contraception , intrauterine device , diaphragm spermicide , cervical cap spermicide female condom spermicide ; spermicides alone acceptable method contraception ) screen 30 day follow last dose study drug . If participant female childbearing potential , must negative serum β human chorionic gonadotropin ( hCG ) pregnancy test screening within 24 hrs prior dose Part 1/Day 2 If participant male female partner ( ) childbearing potential , must agree use medically acceptable method contraception study 30 day last dose study drug . If participant 's partner pregnant , participant must agree use condom . If participant 's partner childbearing potential , must use condom partner must additionally use one follow method : hormonal contraception , intrauterine device , diaphragm spermicide , cervical cap spermicide female condom spermicide . participant must laboratory value within parameter outline study protocol . participant life expectancy &gt; 3 month . participant voluntarily agree participate give write informed consent . Inclusion Criteria Part 2 study : participant enrol comply study procedure Part 1 study . participant willing comply protocol requirement procedures Part 2 study . participant chemotherapy , radiotherapy , biological therapy within 4 week ( 6 week nitrosoureas , mitomycin C , monoclonal antibody ) prior first dose study drug ( Part 1/Day 2 ) recover adverse event due agent administer 4 week earlier . participant receive concurrent anticancer therapy ; participant may receive supportive therapy define study protocol participant receive concurrent treatment immunosuppressive agent , include corticosteroid dos great use replacement therapy . Corticosteroids administer replacement therapy stable dos ≥ 2 week permit . participant clinically significant abnormality electrocardiogram ( ECG ) perform prestudy ( screen ) visit and/or prior administration initial dose study drug . participant significant uncontrolled cardiovascular disease history congestive heart failure , unstable angina , myocardial infarction . Controlled hypertension &lt; 150/100 mm Hg allow participant stable antihypertensive regimen . participant currently participate participate study investigational compound device within 30 day prior first dose study drug . participant primary central nervous system tumor , active brain metastasis leptomeningeal carcinomatosis . participant previously treat brain metastasis stable &gt; 3 month eligible current brain magnetic resonance imaging ( MRI ) ( within 28 day first dose study drug ) show edema evidence progression compare prior MRI study ( ≥ 3 month ago ) . participant history current evidence condition , therapy , lab abnormality might confound result study , interfere participant 's participation full duration study , best interest participant participate . participant know psychiatric disorder would interfere give informed consent cooperating requirement study . participant , time signing informed consent , regular user ( include use illicit drug recent history ( within last year ) drug alcohol abuse . participant pregnant breastfeeding , expect conceive within project duration study . participant know Human Immunodeficiency Virus ( HIV ) positive . participant known history Hepatitis B C. participant newly diagnose ( within 3 month first dose study drug ) poorly control Type 1 2 diabetes . participant require treatment medication inducer inhibitor cytochrome P450 ( CYP3A ) prior first dose study drug ( Part 1/Day 2 ) throughout study poststudy visit . participant currently take history pronounce sedation upon take benzodiazepine sedative/soporific . The washout prestudy use medication least five halflives prior first dose study drug Part 1 ( Part 1/Day 2 ) use Part 1 permit ( use Part 2 permit ) . participant active infection receive intravenous antibiotic , antiviral , antifungal agent within 2 week prior first dose study drug . participant refrain use herbal remedy ( St. John 's Wort , shark cartilage , etc . ) 2 week prior first dose ( Part 1/Day 2 ) throughout duration study . participant anticipate require immunologic therapy , radiation therapy , surgery , chemotherapy study . participant receive highdose chemotherapy stem cell rescue . participant blood transfusion within one week study entry . participant unable swallow capsule and/or document surgical anatomical condition preclude participant swallow absorb oral medication ongoing basis . participant know hypersensitivity component study drug analog macrolide antibiotic ( e.g. , clarithromycin , erythromycin , azithromycin ) . participant allergy hypersensitivity midazolam benzodiazepine . participant refrain consumption grapefruit grapefruit juice approximately 2 week prior first dose ( Part 1/Day 2 ) completion study . participant adequately recovered prior surgical procedure undergone major surgical procedure within 4 week prior first dose study drug . participant undergone minor procedure ( e.g . placement central venous access port ) consider eligible fully recover .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Relapsed refractory advanced cancer , metastatic cancer , locally advanced cancer</keyword>
</DOC>